Answers are grounded in this paper and cite their sources.
The discovery of the enzymatic defects in sphingolipid-storage disorders led to important benefits for patients with these conditions. Diagnostic tests, genetic counseling procedures and prenatal diagnosis are available for these disorders. Enzyme-replacement therapy is especially effective for patients with Gaucher disease. It is also approved for patients with Fabry disease, but as yet unrecognized targets need to be addressed and treatment improved, probably because of the multiplicity of organs and tissues involved in patients with this condition. We propose that a significant increase of our understanding of the pathophysiology and etiopathogenesis underlying Fabry disease and other metabolic storage disorders is probably required to develop effective therapies for these patients. Significant advances in this aspect of Fabry disease and other disorders are anticipated from the application of a system- biology approach to understand the cellular and metabolic consequences of lipid accumulation.
No takes yet. Share an insight, caveat, or question.
Moore et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: